GLYBURIDE AND METFORMIN HYDROCHLORIDE
Clinical safety rating: safe
Alcohol and contrast dye can increase risk of lactic acidosis Can cause lactic acidosis a rare but serious metabolic complication.
Glyburide stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, leading to membrane depolarization and calcium influx. Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
| Metabolism | Glyburide is extensively metabolized in the liver, primarily via CYP2C9, to hydroxylated metabolites. Metformin is not metabolized; it is excreted unchanged in urine. |
| Excretion | Glyburide: ~50% renal, ~50% biliary/fecal. Metformin: 90% renal unchanged, 10% fecal. |
| Half-life | Glyburide: 10 hours (range 7–20 h); Metformin: 6.2 hours (range 4–9 h). Combined effect supports twice-daily dosing. |
| Protein binding | Glyburide: >99% bound to albumin. Metformin: negligible (<5% bound). |
| Volume of Distribution | Glyburide: 0.3 L/kg; Metformin: 1–5 L/kg (large distribution into tissues). |
| Bioavailability | Glyburide: ~100% oral; Metformin: 50–60% oral, food decreases absorption slightly. |
| Onset of Action | Oral: Glyburide onset 30–60 min; Metformin onset 2–3 hours. Clinical effect on glucose seen within 1–2 weeks. |
| Duration of Action | Glyburide: 16–24 hours; Metformin: 8–12 hours. Combination duration supports BID dosing. |
| Molecular Weight | Glyburide: 494.0 Da; Metformin: 165.6 Da (as hydrochloride: 202.1 Da). Combined not applicable; individual values provided. |
Initial: 1.25 mg glyburide/250 mg metformin once daily with meals; titrate up to maximum 20 mg glyburide/2000 mg metformin per day in divided doses.
| Dosage form | TABLET |
| Renal impairment | eGFR ≥60 mL/min: no adjustment; eGFR 45-59 mL/min: reduce dose or consider discontinuation; eGFR <45 mL/min: contraindicated. |
| Liver impairment | Contraindicated in hepatic impairment (Child-Pugh class B or C); use with caution in mild hepatic impairment; consider alternative therapy. |
| Pediatric use | Not recommended for pediatric patients under 18 years due to lack of safety and efficacy data. |
| Geriatric use | Start with lowest dose (1.25 mg/250 mg once daily); avoid use if age >80 years unless normal renal function confirmed; monitor renal function closely. |
| 1st trimester | Use only if potential benefit justifies risk; insulin preferred. Metformin is generally considered acceptable, but glyburide may cause hypoglycemia. Animal studies show effects at high doses. |
| 2nd trimester | Generally avoided; insulin is preferred. Glyburide may cross placenta and cause neonatal hypoglycemia. Metformin is sometimes used off-label for gestational diabetes. |
| 3rd trimester | Avoid near term due to risk of neonatal hypoglycemia. Metformin may be continued if benefits outweigh risks, but glyburide is not recommended. |
Clinical note
Alcohol and contrast dye can increase risk of lactic acidosis Can cause lactic acidosis a rare but serious metabolic complication.
| FDA category | Human |
| Placental transfer | Glyburide: Limited placental transfer (F/M ratio ~0.7) but sufficient to cause neonatal hypoglycemia. Metformin: Extensive transfer; levels similar to maternal. |
■ FDA Black Box Warning
Lactic acidosis: Metformin accumulation can cause lactic acidosis, a rare but serious complication (mortality >50%). Risk increases with renal impairment, age, hypoxia, sepsis, or acute alcohol intoxication. Symptoms include malaise, myalgia, respiratory distress, abdominal pain, hypothermia, and altered consciousness. Prompt discontinuation and hemodialysis may be required.
| Common Effects | Diarrhea |
| Serious Effects |
Renal impairment (eGFR <30 mL/min/1.73 m²)Acute or chronic metabolic acidosis (including diabetic ketoacidosis)Hypersensitivity to glyburide or metforminSevere hepatic impairmentPregnancy and lactation (relative; generally preferred alternative available)
| Precautions | Lactic acidosis risk: avoid in renal impairment (CrCl <30 mL/min), acute or chronic metabolic acidosis, or during intravascular iodinated contrast studies., Hypoglycemia: glyburide component may cause severe hypoglycemia, especially in elderly, debilitated, or malnourished patients., Cardiovascular risk: sulfonylureas may increase cardiovascular mortality (UKPDS warning)., Vitamin B12 deficiency: prolonged metformin use may reduce B12 levels; monitor annually., Hepatic impairment: avoid in liver disease due to increased risk of lactic acidosis., Acute alcohol intake: potentiates metformin effect on lactate metabolism. |
Loading safety data…
| Breastfeeding | Both drugs are excreted into breast milk. Metformin is present in low levels and considered compatible with breastfeeding. Glyburide is excreted in trace amounts; theoretical risk of hypoglycemia in infant. Monitor infant for jaundice, hypoglycemia. Use with caution, especially in preterm infants. |
| Lactation Rating | L3 (Moderately Safe) - combination; metformin is L2, glyburide is L3. Consider alternative if possible. |
| Teratogenic Risk | Glyburide: Pregnancy category B; minimal fetotoxicity noted but no clear teratogenicity. Metformin: Pregnancy category B; not associated with major malformations. First trimester: No increased risk of major birth defects. Second and third trimesters: Monitor for neonatal hypoglycemia with glyburide; metformin may reduce risk of gestational diabetes complications. |
| Fetal Monitoring | Maternal: Renal function, liver function, serum glucose, HbA1c, signs of lactic acidosis (rare). Fetal: Growth scans, amniotic fluid volume, non-stress tests, biophysical profiles in third trimester. Neonatal: Blood glucose monitoring for 24-48 hours after delivery. |
| Fertility Effects | No known negative effects on fertility in males or females. Metformin may improve ovulatory function in women with polycystic ovary syndrome (PCOS). Glyburide does not adversely affect reproduction. |
| Food/Dietary | Avoid excessive alcohol (increases risk of lactic acidosis and hypoglycemia). Take with food to reduce GI side effects and stabilize blood glucose. Maintain consistent carbohydrate intake; avoid high-sugar foods that can cause rebound hyperglycemia. Grapefruit juice may enhance hypoglycemic effect. |
| Clinical Pearls | Combination product: glyburide (sulfonylurea) stimulates insulin secretion; metformin improves insulin sensitivity and decreases hepatic gluconeogenesis. Monitor renal function (eGFR) before initiation; metformin is contraindicated if eGFR <30 mL/min/1.73m². Risk of hypoglycemia increased with skipped meals, excessive alcohol, or renal impairment. Lactic acidosis risk with metformin: discontinue temporarily for acute illness, surgery, or iodinated contrast studies. Titrate dose gradually to minimize GI upset. |
| Patient Advice | Take with meals to reduce gastrointestinal side effects and hypoglycemia risk. · Avoid skipping meals; carry a fast-acting glucose source (e.g., glucose tablets) for hypoglycemia. · Limit alcohol intake; may increase risk of lactic acidosis and hypoglycemia. · Report symptoms of lactic acidosis (unexplained fatigue, muscle pain, abdominal pain, dyspnea) immediately. · Monitor blood glucose as directed; keep a log for dose adjustments. · Do not crush or chew tablets; take whole. · Inform all healthcare providers about this medication, especially before contrast studies or surgery. |